Kawasaki, November 19, 2026: Fujitsu Japan, in collaboration with the National Cancer Center Hospital East (NCCHE) and US-based Paradigm Health, Inc., has confirmed the effectiveness of using artificial intelligence and the Paradigm Platform to enhance the identification of clinical trial candidates, following a joint research study.
The verification study, conducted from June to October 2026, utilized data from 22,334 patients in NCCHE’s Department of Respiratory Medicine to simulate a clinical trial for patients with EGFR gene mutations. By applying a large language model (LLM) to structure electronic medical records and linking this data to the Paradigm Platform, the system identified 57 priority candidates, with clinical evidence provided for each selection.
AI reduces manual review workload
Fujitsu Japan processed and anonymized data for 3,027 lung cancer patients out of the total 22,334, and Paradigm matched 540 patients with EGFR gene mutations using five eligibility criteria. The AI-driven process identified 57 priority candidates, and subsequent physician review confirmed that 51 were promising for trial participation. The automated system reduced the number of patient records requiring manual review by approximately 89% compared to traditional methods.
Plans for commercial service by fiscal 2027
Based on these results, Fujitsu Japan plans to commercialize a service supporting the entire process from candidate screening to clinical trial enrollment, targeting a launch by the end of fiscal year 2027. The company aims to promote wider adoption of the solution in Japanese medical institutions to expand clinical trial capacity and accelerate patient access to new therapies.
Addressing drug loss and data challenges
The joint research addresses the issue of “drug loss,” where new treatments available overseas are not developed or approved in Japan, partly due to complex eligibility criteria and fragmented medical data. The partners used LLMs to structure unstructured data such as treatment histories and genomic information, enabling standardized eligibility assessments and reducing reliance on individual medical expertise.
Organisations and leadership involved
Fujitsu Japan Limited is headquartered in Kawasaki, Kanagawa, Japan, led by Representative Director and CEO Izuru Kokubu. NCCHE, located in Kashiwa, Chiba, is directed by Toshihiko Doi and operates under the National Cancer Center. Paradigm Health, Inc. is based in Columbus, Ohio, USA, with Kent Thoelke as CEO. The Paradigm Platform supports clinical trial operations including patient population analysis, trial site selection, eligibility evaluation, and candidate identification.
Fujitsu Japan said it will continue to promote its “Uvance” business model to streamline clinical trials and improve healthcare quality, aiming to eliminate drug loss and provide broader access to new treatments.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
